Cargando…

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up

Detalles Bibliográficos
Autores principales:	Kurizky, Patricia Shu, Galvão, Letícia Oba, Martins, Gladys Aires
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2019
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007031/ https://www.ncbi.nlm.nih.gov/pubmed/31644629 http://dx.doi.org/10.1590/abd1806-4841.20198358

Ejemplares similares

Lewis-Sumner syndrome associated with infliximab therapy for psoriasis
por: de Oliveira, Karen Fernandes, et al.
Publicado: (2017)

Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding
por: Kurizky, Patricia Shu, et al.
Publicado: (2015)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis
por: Kurizky, Patricia Shu, et al.
Publicado: (2018)

Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis
por: Trídico, Lívia Arroyo, et al.
Publicado: (2017)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13
por: Sakane, Hideo, et al.
Publicado: (2022)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Divergent Gene Activation in Peripheral Blood and Tissues of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis following Infliximab Therapy
por: Rosenberg, Alexander, et al.
Publicado: (2014)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

GENETICS OF PSORIASIS AND PSORIATIC ARTHRITIS
por: Chandran, Vinod
Publicado: (2010)

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
por: Fisher, Anat, et al.
Publicado: (2022)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
por: Castro, Karla R., et al.
Publicado: (2011)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis
por: Hariman, Richard, et al.
Publicado: (2016)

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
por: Matsuura-Otsuki, Yuki, et al.
Publicado: (2017)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity
por: Ruffilli, Ilaria, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
por: Argüelles-Arias, F., et al.
Publicado: (2017)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
por: Campochiaro, Corrado, et al.
Publicado: (2021)

A Case of Phlegmonous Gastritis in a Patient with Psoriatic Arthritis on Infliximab
por: De Davide, Laurence, et al.
Publicado: (2018)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis
por: Barbarroja, Nuria, et al.
Publicado: (2019)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris
por: Bowes, John, et al.
Publicado: (2011)

From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention
por: Zabotti, Alen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b0h7d0brsk752q8irq075sbltp